Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation

Cancer Science

Volumn 99, Issue 8, 2008, Pages 1679-1684

  Inoue, Akira ^a   Xin, Hong ^b   Suzuki, Takuji ^a   Kanehira, Masahiko ^a,b   Kuroki, Yoshio ^c   Fukuhara, Tatsuro ^a   Kikuchi, Toshiaki ^a   Maemondo, Makoto ^d   Nukiwa, Toshihiro ^a   Saijo, Yasuo ^b,e  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Miyagi Cancer Center   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GEFITINIB; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG LAVAGE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; GENE EXPRESSION; HUMANS; LIPOPOLYSACCHARIDES; LUNG DISEASES, INTERSTITIAL; MICE; PNEUMONIA; PROTEIN KINASE INHIBITORS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 49749138952     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00857.x     Document Type: Article

References (43)

1. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237-46.
2. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149-58.
3. Miller VA, Kris MG, Shah N et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103-9.
4. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
5. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
6. Inoue A, Saijo Y, Maemondo M et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 11 (361): 137-9.
7. Ando M, Okamoto I, Yamamoto N et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006; 24 (16): 2549-56.
8. Takano T, Ohe Y, Kusumoto M et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004; 45 (1): 93-104.
9. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA®) monotherapy. Clinical experience in non-small cell lung cancer. Drug Saf 2004; 27: 1081-92.
10. Takeyama K, Dabbagh K, Lee HM et al. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci USA 1999; 96 (6): 3081-6.
11. Takeyama K, Fahy JV, Nadel JA. Relationship of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med 2001 Feb; 163 (2): 511-16.
12. Whitsett JA, Weaver TE, Lieberman MA, Clark JC, Daugherty C. Differential effects of epidermal growth factor and transforming growth factor-beta on synthesis of Mr = 35.000 surfactant-associated protein in fetal lung. J Biol Chem 1987; 262: 7908-13.
13. King RJ, Clements JA. Surface active materials from dog lung. I. Method of isolation. Am J Physiol 1972; 223: 707-14.
14. King RJ, Clements JA. Surface active materials from dog lung. II. Composition and physiological correlations. Am J Physiol 1972; 223: 715-26.
15. Kuroki Y, Voelker DR. Pulmonary surfactant proteins. J Biol Chem 1994; 269: 25943-6.
16. Sano H, Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol 2005; 42: 279-87.
17. Wright JR, Borron P, Brinker KG, Folz RJ. Surfactant protein A regulation of innate and adaptive immune responses in lung inflammation. Am J Respir Cell Mol Biol 2001; 24: 513-7.
18. LeVine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett JA, Korfhagen TR. Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. J Immunol 1997; 1 (158): 4336-40.
19. LeVine AM, Whitsett JA, Gwozdz JA et al. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol 2000; 165: 3934-40.
20. LeVine AM, Kurak KE, Bruno MD, Stark JM, Whitsett JA, Korfhagen TR. Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 1998; 19: 700-8.
21. Linke MJ, Harris CE, Korfhagen TR et al. Immunosuppressed surfactant protein A-deficient mice have increased susceptibility to Pneumocystis carinii infection. J Infect Dis 2001; 183: 943-52.
22. LeVine AM, Gwozdz J, Stark J, Bruno M, Whitsett J, Korfhagen T. Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J Clin Invest 1999; 103: 1015-21.
23. Bridges JP, Davis HW, Damodarasamy M et al. Pulmonary surfactant proteins A and D are potent endogenous inhibitors of lipid peroxidation and oxidative cellular injury. J Biol Chem 2000; 275: 38848-55.
24. Fukazawa T, Maeda Y, Durbin ML et al. Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system. Mol Cancer Ther 2007; 6: 244-52.
25. Mukohara T, Engelman JA, Hanna NH et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97: 1185-94.
26. Kuroki Y, Tsutahara S, Shijubo N et al. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis 1993; 147: 723-9.
27. Madan T, Kishore U, Singh M et al. Surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens. J Clin Invest 2001; 107: 467-75.
28. Nakagawa K, Tamura T, Negoro S et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003; 14: 922-30.
29. Mendelson CR. Role of transcription factors in fetal lung development and surfactant protein gene expression. Annu Rev Physiol 2000; 62: 875-915.
30. Sundell HW, Gray ME, Serenius FS, Escobedo MB, Stahlman MT. Effects of epidermal growth factor on lung maturation in fetal lambs. Am J Pathol 1980; 100: 707-25.
31. Klein JM, DeWild LJ, McCarthy TA. Effect of tyrosine kinase inhibition on surfactant protein A gene expression during human lung development. Am J Physiol 1998; 274 (4 Part 1): L542-51.
32. Klein JM, McCarthy TA, Dagle JM, Snyder JM. Antisense inhibition of epidermal growth factor receptor decreases expression of human surfactant protein A. Am J Respir Cell Mol Biol 2000; 22: 676-84.
33. Sano H, Sohma H, Muta T, Nomura S, Voelker DR, Kuroki Y. Pulmonary surfactant protein A modulates the cellular response to smooth and rough lipopolysaccharides by interaction with CD14. J Immunol 1999; 163: 387-95.
34. Borron P, McIntosh JC, Korfhagen TR, Whitsett JA, Taylor J, Wright JR. Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. Am J Physiol Lung Cell Mol Physiol 2000; 278: L840-7.
35. Murakami S, Iwaki D, Mitsuzawa H et al. Surfactant protein A inhibits peptidoglycan-induced tumor necrosis factor-alpha secretion in U937 cells and alveolar macrophages by direct interaction with toll-like receptor 2. J Biol Chem 2002; 277: 6830-7.
36. Betsuyaku T, Kuroki Y, Nagai K, Nasuhara Y, Nishimura M. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J 2004; 24: 964-70.
37. McCormack FX, King TE Jr, Voelker DR, Robinson PC, Mason RJ. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am Rev Respir Dis 1991; 144: 160-6.
38. McCormack FX, King TE Jr, Bucher BL, Nielsen L, Mason RJ. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 152: 751-9.
39. Tamura K, Okamoto I, Kurata T, Satoh T, Nakagawa K, Fukuoka M. Low expressions of surfactant-associated protein (SP-A) in cancer tissues or in normal bronchial epithelial cells by immuno-histochemistry predict interstitial lung diseases induced by gefitinib in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2005; 23: 667s.
40. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003; 63: 5054-9.
41. Madtes DK, Busby HK, Strandjord TP, Clark JG. Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats. Am J Respir Cell Mol Biol 1994; 11: 540-51.
42. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-84.
43. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-94.